Role of Innate and Adaptive Cytokines in the Survival of COVID-19 Patients.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
07 Sep 2022
Historique:
received: 18 07 2022
revised: 02 09 2022
accepted: 02 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 28 9 2022
Statut: epublish

Résumé

SARS-CoV-2 is a new coronavirus characterized by a high infection and transmission capacity. A significant number of patients develop inadequate immune responses that produce massive releases of cytokines that compromise their survival. Soluble factors are clinically and pathologically relevant in COVID-19 survival but remain only partially characterized. The objective of this work was to simultaneously study 62 circulating soluble factors, including innate and adaptive cytokines and their soluble receptors, chemokines and growth and wound-healing/repair factors, in severe COVID-19 patients who survived compared to those with fatal outcomes. Serum samples were obtained from 286 COVID-19 patients and 40 healthy controls. The 62 circulating soluble factors were quantified using a Luminex Milliplex assay. Results. The patients who survived had decreased levels of the following 30 soluble factors of the 62 studied compared to those with fatal outcomes, therefore, these decreases were observed for cytokines and receptors predominantly produced by the innate immune system-IL-1α, IL-1α, IL-18, IL-15, IL-12p40, IL-6, IL-27, IL-1Ra, IL-1RI, IL-1RII, TNFα, TGFα, IL-10, sRAGE, sTNF-RI and sTNF-RII-for the chemokines IL-8, IP-10, MCP-1, MCP-3, MIG and fractalkine; for the growth factors M-CSF and the soluble receptor sIL2Ra; for the cytokines involved in the adaptive immune system IFNγ, IL-17 and sIL-4R; and for the wound-repair factor FGF2. On the other hand, the patients who survived had elevated levels of the soluble factors TNFβ, sCD40L, MDC, RANTES, G-CSF, GM-CSF, EGF, PDGFAA and PDGFABBB compared to those who died. Conclusions. Increases in the circulating levels of the sCD40L cytokine; MDC and RANTES chemokines; the G-CSF and GM-CSF growth factors, EGF, PDGFAA and PDGFABBB; and tissue-repair factors are strongly associated with survival. By contrast, large increases in IL-15, IL-6, IL-18, IL-27 and IL-10; the sIL-1RI, sIL1RII and sTNF-RII receptors; the MCP3, IL-8, MIG and IP-10 chemokines; the M-CSF and sIL-2Ra growth factors; and the wound-healing factor FGF2 favor fatal outcomes of the disease.

Identifiants

pubmed: 36142255
pii: ijms231810344
doi: 10.3390/ijms231810344
pmc: PMC9499609
pii:
doi:

Substances chimiques

Chemokine CCL5 0
Chemokine CX3CL1 0
Chemokine CXCL10 0
Cytokines 0
Interleukin 1 Receptor Antagonist Protein 0
Interleukin-12 Subunit p40 0
Interleukin-15 0
Interleukin-17 0
Interleukin-18 0
Interleukin-27 0
Interleukin-6 0
Interleukin-8 0
Transforming Growth Factor alpha 0
Tumor Necrosis Factor-alpha 0
Fibroblast Growth Factor 2 103107-01-3
Interleukin-10 130068-27-8
Granulocyte Colony-Stimulating Factor 143011-72-7
Epidermal Growth Factor 62229-50-9
Macrophage Colony-Stimulating Factor 81627-83-0
Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Comunidad de Madrid
ID : MITIC-CM

Références

Cytokine Growth Factor Rev. 2015 Oct;26(5):475-87
pubmed: 26189695
J Inflamm Res. 2021 Apr 16;14:1487-1510
pubmed: 33889008
Immunol Res. 2022 Oct;70(5):578-606
pubmed: 35610534
Nat Rev Rheumatol. 2021 Dec;17(12):749-766
pubmed: 34728817
Immunol Rev. 2019 May;289(1):9-30
pubmed: 30977202
Nat Rev Rheumatol. 2019 Oct;15(10):612-632
pubmed: 31515542
PLoS One. 2021 Dec 2;16(12):e0260623
pubmed: 34855834
PLoS Pathog. 2021 Sep 16;17(9):e1009804
pubmed: 34529726
Medicina (Kaunas). 2022 Jan 18;58(2):
pubmed: 35208467
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Hum Immunol. 2011 Nov;72(11):1013-7
pubmed: 21925225
Sci Adv. 2020 Dec 9;6(50):
pubmed: 33187979
Clin Exp Immunol. 1992 Nov;90(2):161-9
pubmed: 1330388
Front Cardiovasc Med. 2022 Mar 23;9:818890
pubmed: 35402550
Front Immunol. 2020 Aug 18;11:2063
pubmed: 33013872
Annu Rev Immunol. 2014;32:659-702
pubmed: 24655300
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4
pubmed: 32360286
Med Res Rev. 2021 Mar;41(2):1167-1194
pubmed: 33185926
Acta Haematol. 2021;144(4):355-359
pubmed: 32791509
Medicine (Madr). 2021 May;13(33):1917-1931
pubmed: 34075268
Immunity. 2019 Apr 16;50(4):778-795
pubmed: 30995499
Front Immunol. 2017 Aug 04;8:930
pubmed: 28824650
J Leukoc Biol. 2021 Jan;109(1):55-66
pubmed: 32930456
Front Psychiatry. 2018 Jun 14;9:241
pubmed: 29962972
Annu Rev Med. 2015;66:145-59
pubmed: 25386930
Cytokine. 2014 Nov;70(1):11-20
pubmed: 24986424
Comput Struct Biotechnol J. 2021;19:976-988
pubmed: 33558827
Inflamm Regen. 2020 Aug 6;40:19
pubmed: 32834892
Bull Natl Res Cent. 2022;46(1):100
pubmed: 35431536
Front Cardiovasc Med. 2021 Jul 27;8:702507
pubmed: 34386533
J Clin Lab Anal. 2022 Jun;36(6):e24434
pubmed: 35435272
Nat Rev Rheumatol. 2016 May;12(5):259-68
pubmed: 27009539
Transfus Med. 2001 Dec;11(6):403-17
pubmed: 11851938
Pulm Circ. 2020 Nov 25;10(4):2045894020966547
pubmed: 33282193
J Clin Med. 2021 Sep 18;10(18):
pubmed: 34575353
Clin Microbiol Infect. 2021 Feb;27(2):286.e7-286.e13
pubmed: 33045370
Blood Rev. 2009 Jul;23(4):177-89
pubmed: 19450911
Cold Spring Harb Perspect Biol. 2018 Sep 4;10(9):
pubmed: 29038115
Mol Med. 2020 Oct 29;26(1):97
pubmed: 33121429
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Infect Genet Evol. 2020 Nov;85:104569
pubmed: 32979549
Med Hypotheses. 2021 Jun;151:110570
pubmed: 33836338
Front Immunol. 2022 Apr 07;13:832394
pubmed: 35464491
Protein Sci. 2018 Dec;27(12):1984-2009
pubmed: 30267440
Microb Pathog. 2021 Apr;153:104799
pubmed: 33609650
Virol J. 2021 Jun 4;18(1):115
pubmed: 34088324
EBioMedicine. 2021 Apr;66:103317
pubmed: 33813138
J Clin Med. 2022 May 23;11(10):
pubmed: 35629072
Nat Rev Cancer. 2021 Aug;21(8):481-499
pubmed: 34083781
Front Immunol. 2016 Nov 04;7:479
pubmed: 27867385
Biomedicines. 2021 Nov 12;9(11):
pubmed: 34829906
Infect Drug Resist. 2020 Jul 22;13:2485-2493
pubmed: 32801787
Inflamm Regen. 2020 Oct 1;40:37
pubmed: 33014208
Nat Rev Immunol. 2017 Sep;17(9):559-572
pubmed: 28555670
Sci Rep. 2021 Oct 21;11(1):20793
pubmed: 34675240
J Clin Med. 2021 May 08;10(9):
pubmed: 34066892
Int J Infect Dis. 2020 Dec;101:342-345
pubmed: 33039609
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
JCI Insight. 2021 Jul 8;6(13):
pubmed: 34061779
Cell Mol Immunol. 2018 Apr;15(4):295-298
pubmed: 29578534

Auteurs

Jorge Monserrat (J)

Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.

Ana Gómez-Lahoz (A)

Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.

Miguel A Ortega (MA)

Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.
Cancer Registry and Pathology Department, Hospital Universitario Principe de Asturias, 28806 Alcalá de Henares, Spain.

José Sanz (J)

Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias (CIBEREHD), 28806 Alcalá de Henares, Spain.

Benjamin Muñoz (B)

Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias (CIBEREHD), 28806 Alcalá de Henares, Spain.

Juan Arévalo-Serrano (J)

Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias (CIBEREHD), 28806 Alcalá de Henares, Spain.

José Miguel Rodríguez (JM)

Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias (CIBEREHD), 28806 Alcalá de Henares, Spain.

Jose Maria Gasalla (JM)

Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias (CIBEREHD), 28806 Alcalá de Henares, Spain.

Óscar Gasulla (Ó)

Hospital Universitari de Bellvitge, Universitat de Barcelona, 08907 L'Hospitalet de Llobregat, Spain.
Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.

Alberto Arranz (A)

Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.

Jordi Fortuny-Profitós (J)

Campus Nord, Universitat Politècnica de Catalunya, 08034 Barcelona, Spain.

Ferran A Mazaira-Font (FA)

Departament d'Econometria, Estadística I Economia Aplicada, Universitat de Barcelona, 08007 Barcelona, Spain.

Miguel Teixidó Román (M)

Campus Nord, Universitat Politècnica de Catalunya, 08034 Barcelona, Spain.

Carlos Martínez-A (C)

Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, 28006 Madrid, Spain.

Dimitri Balomenos (D)

Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, 28006 Madrid, Spain.

Angel Asunsolo (A)

Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.
Cancer Registry and Pathology Department, Hospital Universitario Principe de Asturias, 28806 Alcalá de Henares, Spain.
Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, University of New York, New York, NY 10027, USA.

Melchor Álvarez-Mon (M)

Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, 28801 Alcalá de Henares, Spain.
Ramón y Cajal Institute of Sanitary Research (IRYCIS), 28034 Madrid, Spain.
Service of Internal Medicine and Immune System Diseases-Rheumatology, University Hospital Príncipe de Asturias (CIBEREHD), 28806 Alcalá de Henares, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH